Amarin Corporation PLC
AMRN
View Detailed Chart
14.920USD
+0.320+2.19%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
309.89MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.19%
5 Days
-0.33%
1 Month
-7.73%
6 Months
+72.41%
Year to Date
+53.81%
1 Year
+25.02%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Sell. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Sell
Current Rating
11.000
Target Price
-26.32%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Overvalued
The company’s latest PE is -2.69, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.85M shares, decreasing 28.83% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 0.00 shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Ticker SymbolAMRN
CompanyAmarin Corporation PLC
CEOMr. Aaron D. Berg
Websitehttps://amarincorp.com/
Related Instruments
-0.35%
-4.12%
+3.22%
+1.88%
+0.75%
-1.87%
+0.72%
+6.30%
+0.83%
+2.41%
-0.11%
+0.02%
+2.31%
+0.70%
+2.93%
+0.93%
+5.59%
+3.22%
0.00%
+2.85%
